CLCheng-Hui Lin

Cheng-Hui Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cheng-Hui Lin has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Sui Wang

    Department of Ophthalmology, Mary M. and Sash A. Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Stanford, CA 94304, USA

    2 shared publications
  • Alexander E. Davis

    Department of Ophthalmology, Mary M. and Sash A. Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Stanford, California, USA

    1 shared publication
  • Baokun Gu

    Department of Ophthalmology, Mary M. and Sash A. Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Stanford, California, USA

    1 shared publication
  • Bin Bao

    Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital; Harvard Medical School, Boston, USA

    1 shared publication
  • Bogdan Tanasa

    Department of Ophthalmology, Mary M. and Sash A. Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Stanford, California, USA

    1 shared publication
  • Candace S. Y. Chan

    Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Dell Paediatric Research Institute, Austin, TX, USA

    1 shared publication

Latest Publications

  • Open Access

    Identification of cis-regulatory modules for adeno-associated virus-based cell-type-specific targeting in the retina and brain

    by Cheng-Hui Lin, Yue Sun, Candace S.Y. Chan, Man-Ru Wu, Lei Gu, Alexander E. Davis, Baokun Gu, Wenlin Zhang, Bogdan Tanasa, Lei R. Zhong, et al.


  • Open Access

    Foxo1 controls gut homeostasis and commensalism by regulating mucus secretion

    by Zuojia Chen, Jialie Luo, Jian Li, Girak Kim, Eric S. Chen, Sheng Xiao, Scott B. Snapper, Bin Bao, Dingding An, Richard S. Blumberg, et al.

    Mucus produced by goblet cells in the gastrointestinal tract forms a biological barrier that protects the intestine from invasion by commensals and pathogens. However, the host-derived regulatory network that controls mucus secretion and thereby changes gut microbiota has not been well studied. Here, we identify that Forkhead box protein O1 (Foxo1) regulates mucus secretion by goblet cells and determines intestinal homeostasis. Loss of Foxo1 in intestinal epithelial cells (IECs) results in defects in goblet cell autophagy and mucus secretion, leading to an impaired gut microenvironment and dysbiosis. Subsequently, due to changes in microbiota and disruption in microbiome metabolites of short-chain fatty acids, Foxo1 deficiency results in altered organization of tight junction proteins and enhanced susceptibility to intestinal inflammation. Our study demonstrates that Foxo1 is crucial for IECs to establish commensalism and maintain intestinal barrier integrity by regulating goblet cell function.


  • Open Access

    Multiple sleep latency test in narcolepsy type 1 and narcolepsy type 2: A 5‐year follow‐up study

    by Yu‐Shu Huang, Christian Guilleminault, Cheng‐Hui Lin, Chia‐Hsiang Chen, Wei‐Chih Chin, Tzu‐Shuang Chen

    Summary: Excessively sleepy teenagers and young adults without sleep‐disordered breathing are diagnosed with either narcolepsy type 1 or narcolepsy type 2, or hypersomnia, based on the presence/absence of cataplexy and the results of a multiple sleep latency test. However, there is controversy surrounding this nomenclature. We will try to find the differences between different diagnoses of hypersomnia from the results of the long‐term follow‐up evaluation of a sleep study. We diagnosed teenagers who had developed excessive daytime sleepiness based on the criteria of the International Classification of Sleep Disorders, 3rd edition. Each individual received the same clinical neurophysiologic testing every year for 5 years after the initial diagnosis of narcolepsy type 1 (n = 111) or type 2 (n = 46). The follow‐up evaluation demonstrated that narcolepsy type 1 (narcolepsy‐cataplexy) is a well‐defined clinical entity, with very reproducible clinical neurophysiologic findings over time, whereas patients with narcolepsy type 2 presented clear clinical and test variability. By the fifth year of the follow‐up evaluation, 17.6% of subjects did not meet the diagnostic criteria of narcolepsy type 2, and 23.9% didn't show any two sleep‐onset rapid eye movement periods in multiple sleep latency during the 5‐year follow‐up. Therefore narcolepsy type 1 (narcolepsy‐cataplexy) is a well‐defined syndrome, with the presentation clearly related to the known consequences of destruction of hypocretin/orexin neurons. Narcolepsy type 2 covers patients with clinical and test variability over time, thus bringing into question the usage of the term “narcolepsy” to label these patients.